ExpreS2ion and Abivax enter agreement to develop Ebola treatment

15-12-2016

Denmark-based ExpreS2ion Biotechnology and Abivax, a French biotechnology company, have entered into a service and commercial licensing agreement under which the companies will collaborate in their development of a treatment for Ebola.


Expres2ion, Abivax, collaboration, licensing agreement, Ebola

LSIPR